Alpha-1 Antitrypsin Deficiency: Principles of Care

Detalhes bibliográficos
Autor(a) principal: Rodrigues, Joana F
Data de Publicação: 2020
Outros Autores: Mineiro, Alexandra, Reis, António, Ventura, David G., Fernandez-Llimos, Fernando, Costa, Filipa, Gomes, Joana, Silva, José Manuel, Lopes, Paulo, Cordeiro, Carlos R.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/105540
https://doi.org/10.20344/amp.12950
Resumo: Alpha-1 antitrypsin deficiency is an autosomal co-dominant inherited disorder that results in decreased circulating levels of alpha-1 antitrypsin (also known as alpha-1 proteinase inhibitor) and predisposes affected individuals to early onset lung and liver disease. There is currently no cure for alpha-1 antitrypsin deficiency. However, appropriate treatment and a high standard of clinical care can prevent patients from being seriously affected and having to undergo major medical interventions, such as organ transplantation. Beyond managing the symptoms associated with alpha-1 antitrypsin deficiency, alpha-1 proteinase inhibitor therapy is the only treatment for the condition's underlying cause. Early diagnosis is important to ensure efficient therapeutic strategies and to minimize further deterioration of lung function. alpha-1 antitrypsin deficiency is under diagnosed globally, partly because the disease has no unique presenting symptoms. This document was prepared by a Portuguese multidisciplinary group and it aims to set out comprehensive principles of care for Alpha-1 antitrypsin deficiency. These include the importance of registries, the need for clinical research, the need for consistent recommendations (regarding diagnosis, treatment and monitoring), the role of reference centres, the requirement for sustained access to treatment, diagnostic and support services, and the role of patient organizations.
id RCAP_77aa9b253b89f50d3af34d8e8f2aa35f
oai_identifier_str oai:estudogeral.uc.pt:10316/105540
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Alpha-1 Antitrypsin Deficiency: Principles of Carealpha 1-Antitrypsin Deficiency/therapyHealth Care Quality, Access, and EvaluationProfessional PracticeStandard of CareAcesso e Avaliação dos Cuidados de SaúdeDeficiência de alfa 1–Antitripsina/tratamento;Padrão de CuidadoQualidade, Prática ProfisionalHumansPractice Guidelines as Topicalpha 1-Antitrypsin DeficiencyStandard of CareAlpha-1 antitrypsin deficiency is an autosomal co-dominant inherited disorder that results in decreased circulating levels of alpha-1 antitrypsin (also known as alpha-1 proteinase inhibitor) and predisposes affected individuals to early onset lung and liver disease. There is currently no cure for alpha-1 antitrypsin deficiency. However, appropriate treatment and a high standard of clinical care can prevent patients from being seriously affected and having to undergo major medical interventions, such as organ transplantation. Beyond managing the symptoms associated with alpha-1 antitrypsin deficiency, alpha-1 proteinase inhibitor therapy is the only treatment for the condition's underlying cause. Early diagnosis is important to ensure efficient therapeutic strategies and to minimize further deterioration of lung function. alpha-1 antitrypsin deficiency is under diagnosed globally, partly because the disease has no unique presenting symptoms. This document was prepared by a Portuguese multidisciplinary group and it aims to set out comprehensive principles of care for Alpha-1 antitrypsin deficiency. These include the importance of registries, the need for clinical research, the need for consistent recommendations (regarding diagnosis, treatment and monitoring), the role of reference centres, the requirement for sustained access to treatment, diagnostic and support services, and the role of patient organizations.A deficiência de alfa-1 antitripsina é uma doença hereditária autossómica co-dominante que resulta numa diminuição dos níveis plasmáticos de alfa-1 antitripsina (também conhecida por inibidor da alfa-1 proteinase) e predispõe os indivíduos afetados ao desenvolvimento de doença pulmonar e hepática precoce. Atualmente não existe cura para a deficiência de alfa-1 antitripsina. No entanto, o tratamento adequado e um elevado padrão de cuidados clínicos podem prevenir que os doentes sejam gravemente afetados e terem que se submeter a intervenções médicas major, como o transplante de órgão. Para além de atuar nos sintomas associados à deficiência de alfa-1 antitripsina, a terapêutica com o inibidor da alfa-1 proteinase é o único tratamento disponível que atua na causa subjacente desta patologia. O diagnostico precoce é importante para assegurar a implementação de estratégias terapêuticas eficientes e para minimizar a destruição adicional da função pulmonar. A deficiência de alfa-1 antitripsina está globalmente sub diagnosticada, em parte devido ao fato desta doença não apresentar sintomas únicos. Este documento foi preparado por um grupo multidisciplinar e visa estabelecer princípios de cuidados abrangentes para a deficiência de alfa-1 antitripsina. Estes incluem a importância dos registros, a necessidade de investigação clinica, a necessidade de recomendações consistentes (no que diz respeito ao diagnostico, tratamento e monitorização), o papel dos centros de referência, a necessidade de acesso sustentado ao tratamento, diagnostico e serviços de suporte, e o papel das associações de doentes.Ordem dos Médicos2020-06-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/105540http://hdl.handle.net/10316/105540https://doi.org/10.20344/amp.12950eng1646-07580870-399XRodrigues, Joana FMineiro, AlexandraReis, AntónioVentura, David G.Fernandez-Llimos, FernandoCosta, FilipaGomes, JoanaSilva, José ManuelLopes, PauloCordeiro, Carlos R.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-06T12:25:13Zoai:estudogeral.uc.pt:10316/105540Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:22:06.084542Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Alpha-1 Antitrypsin Deficiency: Principles of Care
title Alpha-1 Antitrypsin Deficiency: Principles of Care
spellingShingle Alpha-1 Antitrypsin Deficiency: Principles of Care
Rodrigues, Joana F
alpha 1-Antitrypsin Deficiency/therapy
Health Care Quality, Access, and Evaluation
Professional Practice
Standard of Care
Acesso e Avaliação dos Cuidados de Saúde
Deficiência de alfa 1–Antitripsina/tratamento;
Padrão de Cuidado
Qualidade, Prática Profisional
Humans
Practice Guidelines as Topic
alpha 1-Antitrypsin Deficiency
Standard of Care
title_short Alpha-1 Antitrypsin Deficiency: Principles of Care
title_full Alpha-1 Antitrypsin Deficiency: Principles of Care
title_fullStr Alpha-1 Antitrypsin Deficiency: Principles of Care
title_full_unstemmed Alpha-1 Antitrypsin Deficiency: Principles of Care
title_sort Alpha-1 Antitrypsin Deficiency: Principles of Care
author Rodrigues, Joana F
author_facet Rodrigues, Joana F
Mineiro, Alexandra
Reis, António
Ventura, David G.
Fernandez-Llimos, Fernando
Costa, Filipa
Gomes, Joana
Silva, José Manuel
Lopes, Paulo
Cordeiro, Carlos R.
author_role author
author2 Mineiro, Alexandra
Reis, António
Ventura, David G.
Fernandez-Llimos, Fernando
Costa, Filipa
Gomes, Joana
Silva, José Manuel
Lopes, Paulo
Cordeiro, Carlos R.
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Rodrigues, Joana F
Mineiro, Alexandra
Reis, António
Ventura, David G.
Fernandez-Llimos, Fernando
Costa, Filipa
Gomes, Joana
Silva, José Manuel
Lopes, Paulo
Cordeiro, Carlos R.
dc.subject.por.fl_str_mv alpha 1-Antitrypsin Deficiency/therapy
Health Care Quality, Access, and Evaluation
Professional Practice
Standard of Care
Acesso e Avaliação dos Cuidados de Saúde
Deficiência de alfa 1–Antitripsina/tratamento;
Padrão de Cuidado
Qualidade, Prática Profisional
Humans
Practice Guidelines as Topic
alpha 1-Antitrypsin Deficiency
Standard of Care
topic alpha 1-Antitrypsin Deficiency/therapy
Health Care Quality, Access, and Evaluation
Professional Practice
Standard of Care
Acesso e Avaliação dos Cuidados de Saúde
Deficiência de alfa 1–Antitripsina/tratamento;
Padrão de Cuidado
Qualidade, Prática Profisional
Humans
Practice Guidelines as Topic
alpha 1-Antitrypsin Deficiency
Standard of Care
description Alpha-1 antitrypsin deficiency is an autosomal co-dominant inherited disorder that results in decreased circulating levels of alpha-1 antitrypsin (also known as alpha-1 proteinase inhibitor) and predisposes affected individuals to early onset lung and liver disease. There is currently no cure for alpha-1 antitrypsin deficiency. However, appropriate treatment and a high standard of clinical care can prevent patients from being seriously affected and having to undergo major medical interventions, such as organ transplantation. Beyond managing the symptoms associated with alpha-1 antitrypsin deficiency, alpha-1 proteinase inhibitor therapy is the only treatment for the condition's underlying cause. Early diagnosis is important to ensure efficient therapeutic strategies and to minimize further deterioration of lung function. alpha-1 antitrypsin deficiency is under diagnosed globally, partly because the disease has no unique presenting symptoms. This document was prepared by a Portuguese multidisciplinary group and it aims to set out comprehensive principles of care for Alpha-1 antitrypsin deficiency. These include the importance of registries, the need for clinical research, the need for consistent recommendations (regarding diagnosis, treatment and monitoring), the role of reference centres, the requirement for sustained access to treatment, diagnostic and support services, and the role of patient organizations.
publishDate 2020
dc.date.none.fl_str_mv 2020-06-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/105540
http://hdl.handle.net/10316/105540
https://doi.org/10.20344/amp.12950
url http://hdl.handle.net/10316/105540
https://doi.org/10.20344/amp.12950
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1646-0758
0870-399X
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1817552189296476160